Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1985:29 Suppl 2:16-25.
doi: 10.2165/00003495-198500292-00005.

Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol

Clinical Trial

Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol

O Rönn et al. Drugs. 1985.

Abstract

In a single-blind randomised study in 9 healthy men we compared the acute haemodynamic effects of the calcium antagonists felodipine and verapamil, singly and in combination with metoprolol. Three different cumulative intravenous doses of 0.25, 0.75 and 1.5 mg felodipine and of 2.0, 4.0 and 8.0 mg verapamil or placebo were given as constant infusions over 5 minutes on 3 occasions and were followed by intravenous metoprolol (15 mg). Felodipine caused a significant and dose-dependent decrease in the total peripheral resistance, and an increase in the forearm blood flow by 8, 48 and 163% with progressively increasing doses showing that the drug is a potent arteriolar vasodilator. A significant and dose-dependent increase in heart rate and a decrease in the pre-ejection period/left ventricular ejection time (PEP/LVET) ratio of up to 15% was also recorded, mainly reflecting a reflexogenic increase in the sympathetic tone. Total peripheral resistance, forearm blood flow, heart rate and the systolic time intervals were mainly unchanged after verapamil, whereas the PQ interval was prolonged. Metoprolol given after the 2 calcium antagonists caused a decrease in heart rate and blood flow and an increase in the total peripheral resistance and PEP/LVET ratio. The tolerability was good to all infusions.

PubMed Disclaimer

References

    1. Eur J Clin Pharmacol. 1983;24(1):49-53 - PubMed
    1. J Pharm Sci. 1981 Jul;70(7):800-1 - PubMed
    1. Br J Clin Pharmacol. 1984 Mar;17(3):257-63 - PubMed
    1. Circulation. 1982 Apr;65(4):660-8 - PubMed
    1. Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 5):136-44 - PubMed

Publication types

MeSH terms

LinkOut - more resources